Alzheimer’s
Alzheimer’s Drug Lecanemab Can Slow Disease Progression by Over Eight Years, Says New Research
New research presented at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego suggests that the Alzheimer’s drug lecanemab, licensed in the UK but not available on the NHS, can slow disease progression …
